agents. Therefore, it is essential to search for novel antimetastatic agents that are efficient and have minimum side effects.
Herbs have recently become attractive as physiologically functional foods, as well as source material for the development of pharmacologically active drugs. Herbal medicines derived from plant extracts are increasingly being used to treat a wide variety of clinical conditions, with relatively little knowledge of their modes of action. Biophytum sensitivum (L.) DC (Oxalidaceae) has been used as food and in traditional oriental medicine to treat diabetes and inflammation. 3, 4 It was previously reported that B sensitivum possesses many pharmacologically active compounds such as luteolin 7-methyl ester, iso-orientin, cupressuflavone, and amentoflavone. 5 We had reported that B sensitivum T umor metastasis, the process by which tumor cells leave the primary tumor to colonize other sites of the body, is a major cause of death for cancer patients. Metastasizing cells must first disseminate from the primary tumor, invade the surrounding tissue, intravasate and extravasate the circulatory system, arrest, initiate angiogenesis, and colonize distant sites while evading the immune system. 1, 2 Compounds that block or suppress the metastatic cascade have potential as anticancer
Biophytum sensitivum (L.) DC Inhibits Tumor Cell Invasion and Metastasis Through a Mechanism Involving Regulation of MMPs, Prolyl Hydroxylase, Lysyl Oxidase, nm23, ERK-1, ERK-2, STAT-1, and Proinflammatory Cytokine Gene Expression in Metastatic Lung Tissue
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Biophytum sensitivum is a traditional oriental herbal medicine that is known for its immunostimulatory and antitumor effects. Tumor metastasis is the most important cause of cancer death. Although B sensitivum was shown to inhibit metastasis, the mechanism underlying this action is not well understood. In the present report, the authors had studied the effect of B sensitivum on the invasion and motility of B16F-10 melanoma cells and investigate the regulatory effect on the expression of matrix metalloproteases (MMPs), prolyl hydoxylase, lysyl oxidase, nm23, extracellular signal-regulated kinase (ERK)-1, ERK-2, signal transducer and activator of transcription (STAT)-1, and proinflammatory cytokines in metastatic tumor-bearing lungs. B sensitivum inhibited the invasion and motility of B16F-10 cells in a dose-dependent manner. B sensitivum inhibited the expression of MMP-2 and MMP-9, whereas it activated STAT-1 expression in metastatic tumor-bearing lungs. Similarly, inhibition of prolyl hydroxylase, lysyl oxidase, ERK-1, ERK-2, and vascular endothelial growth factor (VEGF) expression but activation of nm23 by B sensitivum was observed in metastatic tumor-bearing lungs. B sensitivum treatment also downregulated the expression of tumor necrosis factor-α, interleukin (IL)-1β, IL-6, and granulocyte monocyte-colony stimulating factor in metastatic tumorbearing lungs. In B16F-10 cells, B sensitivum also inhibited the production of proinflammatory cytokines. Overall, the results indicate that B sensitivum exhibits antimetastatic effects through the inhibition of invasion and motility. The results also suggest that MMPs, prolyl hydroxylase, lysyl oxidase, nm23, ERKs, VEGF, STAT, and proinflammatory cytokines are critical regulators of the B sensitivum-mediated antimetastatic effect.
Keywords: Biophytum sensitivum, invasion, motility, cytokine expression, chemoprevention possesses antioxidant effects and immunomodulatory as well as antitumor effects and inhibits B16F-10-induced experimental angiogenesis. [6] [7] [8] Recently, we reported that B sensitivum exhibits antimetastatic activity and inhibits the cytokine production and activation as well as nuclear translocation of p65, p50, c-Rel subunits of nuclear factor-κB, and other transcription factors such as c-fos, activated transcription factor-2, and cyclic adenosine monophosphate response element-binding protein in B16F-10 melanoma cells. 9 Prompted by these observations, we have used in vitro systems of experimental metastasis as well as carried out expression studies of matrix metalloprotease (MMP)-2, MMP-9, prolyl hydroxylase, lysyl oxidase, nm-23, extracellular signal-regulated kinase (ERK)-1, ERK-2, signal transducer and activator of transcription (STAT)-1, and proinflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and granulocyte monocyte-colony stimulating factor (GM-CSF) in metastatic tumor-bearing lungs in parallel studies to investigate whether these genes play an important role in Biophytummediated inhibition of metastasis.
Materials and Methods
Materials
Dulbecco's modified Eagle's medium (DMEM) was obtained from Himedia (Mumbai, India). Fetal bovine serum (FBS) was procured from Life Technologies (Grand Island, NY). MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) was purchased from Sigma Chemicals (St Louis, MO). Oligonucleotide primer sequences of genes for reverse transcription polymerase chain reaction were purchased from Maxim Biotech (San Francisco, CA). Radioactive thymidine [ 3 H] was purchased from BRIT (Mumbai, India). Highly specific quantitative sandwich enzyme-linked immunosorbent assay kits for mouse TNF-α, IL-1β, IL-6, and GM-CSF were purchased from Pierce Biotechnology (Rockford, IL).
Cells
The B16F-10 melanoma cell line was originally obtained from the National Centre for Cell Science (Pune, India). The cells were maintained in DMEM supplemented with 10% FBS and antibiotics. The cell line was split regularly before attaining 70% to 80% confluence. The cells were cultured in a humidified incubator in 5% CO 2 in air and were maintained in continuous exponential growth by twice-a-week passage.
Preparation of B sensitivum Extract
Authenticated B sensitivum was collected from Amala Ayurveda Pharmacy, Thrissur, India. A voucher specimen with number ACRC-Ox 07 was deposited at the herbarium of Amala Cancer Research Centre, Thrissur, India. The airdried whole plant (100 g) was powdered and extracted overnight by maceration with 10 volumes of 75% methanol. The solvent was evaporated to dryness at 42°C under reduced pressure using a rotary evaporator. The yield of the extract was 12%.
Animals and Treatment
Adult (5-to 6-week-old) male C57BL/6 mice (22-25 g) were procured from the National Institute of Nutrition (Hyderabad, India). The animals were kept at 23°C ± 1°C in a controlled environment (12-hour light/12-hour dark). They were fed with mouse chow (Sai Feeds, Mumbai, India) and water ad libitum. All the animal experiments were performed according to the rules and regulations of the Institutional Animal Ethics Committee, Government of India.
Metastasis was induced by injecting once with B16F-10 cells (10 6 cells) into the lateral tail vein. B sensitivum administration (50 mg/kg body weight in 0.1% gum acacia intraperitoneally) was started simultaneously and continued for 10 consecutive days at 24-hour intervals.
At the end of the experiment (21 days after tumor injection), the mice were killed by decapitation. The lungs, liver, kidneys, heart, and spleen were examined. The number of pulmonary tumors was determined by counting visible tumor foci. 10
Cell Viability
B16F-10 cells were treated with escalating concentrations of B sensitivum (1-10 µg/mL) for 24 hours at 37°C in a 5% CO 2 humidified incubator. Following treatment, cell viability was determined by MTT assay.
Invasion Assay
The invasive activity of the tumor cells was examined in a modified Boyden chamber using a method described elsewhere. 11 The polycarbonate filters were coated with 25 µg collagen and placed in Boyden chambers. The lower compartment of the chamber was filled with serum-free DMEM, and B16F-10 cells (10 5 cells/ chamber) in DMEM were then seeded in the upper chamber. Escalating concentrations of B sensitvum (1-10 µg/mL) were then added to the upper chamber and incubated for 10 hours at 37°C in 5% CO 2 . The number of invaded cells through the collagen-coated polycarbonate filter was measured by counting cells stained with 0.2% crystal violet solution.
Migration Assay
The migration assay of the tumor cells was carried out using the Boyden chamber. The polycarbonate filters were placed in Boyden chambers. The lower compartment of the chamber was filled with serum-free DMEM, and B16F-10 cells (10 5 cells/ chamber) in DMEM were then seeded in the upper chamber. Escalating concentrations of B sensitivum (1-10 µg/mL) were then added to the upper chamber and incubated for 10 hours at 37°C in 5% CO 2 . The number of migrated cells in the lower compartment was measured by hemocytometer counting.
Proliferation Assay
B16F-10 melanoma cells (5 × 10 3 cells/well) were seeded in a 96-well, flat-bottom titer plate and incubated at 37°C in 5% CO 2 atmosphere. After 24 hours, escalating concentrations of B sensitivum (1-10 µg/mL) were added and further incubated for 48 hours. 3 H-thymidine was added to each well (1 µCi/well), and incubation was continued for an additional 18 hours. After completing incubation, the plates were centrifuged, the culture supernatant was removed, and the cells were washed 3 times with phosphate-buffered saline and then treated with ice-cold perchloric acid for 15 minutes. The precipitate obtained was dissolved in 0.5 N NaOH, transferred to scintillation fluid, and kept overnight in the dark. The radioactivity was counted using a Rack Beta liquid scintillation counter (Wallac 1209; Pharmacia, Uppsala, Sweden). All determinations were made in triplicate.
Expression Studies
Total RNA was isolated from the lungs, and cDNA was synthesized using Moloney murine leukemia virus reverse transcriptase. Amplification was performed using specific primers of MMP-2, MMP-9, prolyl hydroxylase, lysyl oxidase, nm23, ERK-1, ERK-2, STAT-1, vascular endothelial growth factor (VEGF), and proinflammatory cytokines such as TNF-α, IL-1β, IL-6, and GM-CSF ( Table 1 ). The amplified products were electrophoresed on a 1.8% agarose gel, stained with ethidium bromide, and photographed under ultraviolet light.
Statistical Analysis
All data are presented as the mean ± standard deviation. Significant differences among the groups were determined using the unpaired Student t test. A value of P < .05 was accepted as an indication of statistical significance. All the figures shown in this article were obtained from at least 3 independent experiments.
Results
Inhibition of Experimental Metastasis by B sensitivum
At the time the animals were killed (21 days after tumor injection), metastatic nodules were clearly noted microscopically in the lungs of mice receiving a tail vein injection with B16F-10 cells, whereas only slight nodules were observed in the group treated with B sensitivum. Treatment of B sensitivum (50 mg/kg) significantly decreased the tumor nodules to 12.5 ± 5.0 (P < 0.001) from 250 ± 25 in the tumor controls ( Figure 1) . Minimal nodules were observed in livers, and no nodules were found in any other organs examined (data not shown).
B sensitivum Inhibits MMP-2, MMP-9, Invasiveness, and Motility
Recent studies have suggested that MMPs play a key role in both the promotion and metastatic progression of several cancers. 12, 13 As shown in Figure 2 , the expression of MMP-2 and MMP-9 was markedly inhibited in B sensitivum-treated metastatic lungs, indicating a preferential downregulation of MMP-2 and MMP-9 by B sensitivum in B16F-10 cells. Invasion and migration of B16F-10 
Forward 5′-CGTCCCGTAGACAAAATGGT-3′ 527 Reverse 5′-CCTTCCACAATGCCAAAGTT-3′ NOTE: bp = base pairs; ERK = extracellular signal-regulated kinase; GAPDH = reduced glyceraldehyde phosphate dehydrogenase; GM-CSF = granulocyte moncytecolony stimulating factor; IL, interleukin; MMP = matrix metalloprotease; STAT = signal transducer and activator of transcription; TNF = tumor necrosis factor; VEGF = vascular endothelial growth factor. cells were also significantly inhibited by B sensitivum (Figures 3 and 4 ), suggesting that MMP-2 and MMP-9 are essential for the invasion/migration of B16F-10 cells. Survival of the cells treated with B sensitivum for up to 24 hours was comparable to that of cells at 0 hours as determined by the MTT assay (data not shown), indicating that the inhibition of invasion and motility was not due to the B sensitivum cytotoxicity. Also, our results indicate that B sensitivum inhibited the proliferation of B16F-10 cells ( Figure 5) .
B sensitivum Inhibits Lysyl Oxidase and Prolyl Hydroxylase Expression in Metastatic Lungs
Lysyl oxidase and prolyl hydroxylase function as extracellular matrix-modulating enzymes. From Figure 6 , it is evident that B sensitivum treatment inhibits lysyl oxidase and prolyl hydroxylase expression in metastatic lungs, resulting in reduced lung fibrosis and dense collagen fibers (desmoplasia) in B sensitivum-treated metastatic lungs (data not shown).
B sensitivum Inhibits VEGF Production in Metastatic Lungs
To determine whether VEGF production is inhibited by B sensitivum, we assessed the production of VEGF mRNA in B sensitivum-treated B16F-10 cells as well as VEGF mRNA expression in B sensitivum-treated metastatic lungs. The tissue VEGF mRNA expression was significantly increased in the tumor control group (Figure 6 ). As compared with the tumor control, B sensitivum treatment decreased the expression of VEGF mRNA. Interestingly, the levels of VEGF mRNA were also significantly decreased by B sensitivum treatment (data not shown). Taken together, our results indicate that B sensitivum treatment decreases VEGF production by inhibiting mRNA expression.
B sensitivum Stimulates STAT-1 and nm23 Expression in Metastatic Lungs
To examine the potency of inhibition of metastatic properties by B sensitivum, we observed the effect of B sensitivum on the STAT-1 and nm23 expression in metastatic lungs. The present results indicate that B sensitivum treatment could increase the expression of STAT-1 and nm23 in metastatic lungs ( Figure 6 ). Interestingly, the increased expression of these genes is accompanied with decreased tumor invasion and motility (Figures 3 and 4) .
B sensitivum Inhibits ERK-1 and ERK-2 Expression in Metastatic Lungs
The ERK pathway is expected to result in antimetastatic as well as antiangiogenic effects. 14 the antimetastatic effect of B sensitivum is mediated through the modulation of the ERK pathway, we examined the expression studies of ERK-1 and ERK-2 in metastatic lungs. The tissue ERK-1 and -2 expression was significantly increased in the tumor control group (Figure 6) . B sensitivum treatment decreased the expression of ERK-1 and -2 mRNA in metastatic lungs.
B sensitivum Inhibits the Expression of Proinflammatory Cytokines TNF-α α, IL-1β β, IL-6, and GM-CSF
To determine the regulatory effect of B sensitivum in the production of proinflammatory cytokines such as TNF-α, IL-1β, IL-6, and GM-CSF, we carried out the expression studies of these genes in metastatic lungs. Our results indicate that B sensitivum could inhibit the expression of these proinflammatory cytokines in metastatic lungs ( Figure 7A ). By contrast, the higher levels of these cytokines in B16F-10 culture supernatant were significantly decreased by B sensitivum treatment ( Figure 7B ).
Discussion
Several antimetastatic drugs or compounds for cancer have been found in natural products. Paclitaxel was identified as a component of the Pacific yew, Taxus brevifolis, and is used as an anticancer drug. 15 Curcumin and catechin were reported to strongly inhibit lung metastasis induced by melanoma cells in mice. 16 All these compounds are derived from plants. Our present study showed that B sensitivum treatment could significantly inhibit experimental lung metastasis induced by B16F-10 melanoma cells in C57BL/6 mice (Figure 1 ). Figure 6 . Effect of Biophytum sensitivum (BS) on the lysyl oxidase, prolyl hydroxylase, vascular endothelial growth factor (VEGF), signal transducer and activator of transcription 1 (STAT-1), nm23, and extracellular signal-regulated kinase (ERK)-1 and ERK-2 gene expression. Total RNA was extracted from the lungs, and complementary DNA was synthesized using Moloney murine leukemia virus reverse transcriptase. Polymerase chain reaction was performed using specific primers for lysyl oxidase, prolyl hydroxylase, VEGF, STAT-1, nm23, ERK-1, and ERK-2. C indicates control; GAPDH = reduced glyceraldehyde-phosphate dehydrogenase. Tumor cell migration and invasion to the extracellular matrix is an important step in the process of tumor metastasis and involves the attachment of tumor cells to the extracellular matrix. 17, 18 In this study, we showed that B sensitivum inhibited the metastasis of the highly metastatic melanoma cell line, B16F-10 cells, as evidenced by decreased cell migration and invasion in a dose-dependent manner up to 10 µg/mL. These findings indicate that B sensitivum exhibits an antimetastatic effect. This is the first report to suggest that B sensitivum inhibits MMPs, which are involved in the invasion and metastasis by degradation of the extracellular matrix. Among members of the MMP family, MMP-2 and MMP-9 (also known as type IV collagenases or gelatinases) appear to be important, and increased expression of MMP-2 and/or MMP-9 has been frequently observed in many human cancers with invasive and metastatic capability. [19] [20] [21] [22] Our results indicate that B sensitivum could inhibit the expression of MMP-2 and MMP-9 in B16F-10 melanoma cells. Therefore, it is possible that one of the major steps by which B sensitivum exhibits an antimetastatic effect is through inhibition of MMP expression. We had indeed demonstrated previously that B sensitivum could activate the expression of tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2, the inhibitors of MMP-2 and MMP-9. 9 Our results indicate that B sensitivum could induce the expression of STAT-1, a member of the STAT family of transcription factors. The STAT proteins control major cellular events such as differentiation, proliferation, cell survival, apoptosis, angiogenesis, and metastasis. 23 Among the STAT proteins, STAT-1 has been considered a target of anticancer therapy because these proteins inhibit tumor growth and metastasis by inhibiting angiogenesis. 23 Various cytokines have been reported to stimulate STAT-1 gene expression, and the major one among them is interferon-γ (IFN-γ). 24, 25 The activation of the STAT-1 signaling pathway by IFN-γ can lead to the expression of caspase-1 and apoptosis. 26, 27 Our previous reports show that B sensitivum could enhance the production of IFN-γ in tumor-bearing animals. 28 Thus, it is possible that the B sensitivuminduced STAT-1 gene expression observed in our studies is mediated through increased production of IFN-γ.
The ERK signaling pathway, also known as the p42/p44 mitogen-activated protein kinase (MAPK) pathway, is a major determinant in the control of cell growth, cell differentiation, and cell survival. This pathway, which operates downstream of Ras, is often upregulated in tumors and represents an attractive target for anticancer therapy. Although the ERK pathway, like the JNK pathway and the p38 MAPK pathway, participates in the regulation of a wide range of biological processes, it has been linked particularly to the control of cell proliferation, cell differentiation, and cell survival. 29, 30 Inhibition of the ERK pathway is expected to result in antimetastatic as well as antiangiogenic effects. 14 Sebolit-Leoopold 31 reported that specific blockade of the ERK pathway in colon tumor cells has been shown to inhibit the alterations in cell-cell contact and that motility that is required for metastasis. Several potent inhibitors of the ERK pathway have been reported, but the development of new small-molecule inhibitors with enhanced bioavailability remains a current priority. Recently, purvalanol, one of the more potent cyclindependent kinase inhibitors to date, has been shown to target ERK-1 and ERK-2. 32 Our results indicate that B sensitivum inhibited the expression of ERK-1 and ERK-2. The mechanism by which B sensitivum inhibits ERK-1 and ERK-2 remains unclear.
Our results indicate that B sensitivum could inhibit the expression of VEGF mRNA in metastatic lungs. VEGF, a major angiogenic factor, is overexpressed by tumor cells and plays an important role in the process of neovascularization and metastasis. 33 Our previous reports show that B sensitivum could inhibit the production of VEGF in angiogenesis-induced animals. 8 Since the ERK pathway plays a crucial role in the transcriptional regulation of VEGF expression, 34 we suspect that the inhibition of VEGF expression by B sensitivum might be mediated through inhibition of the ERK pathway. Further studies in this field are under investigation in our laboratory.
The decrease in metastasis-associated phenotypes, such as cell migration and cell invasion, induced by B sensitivum treatment may be mediated in part by its upregulation of nm23 expression because these effects are highly correlated. Nm23 is a tumor metastasis suppressor gene, 35 and decreased expression of this gene has been found in some primary lesions of human metastatic hepatoma. 36, 37 The increased expression of nm23 mRNA in response to B sensitivum may rely entirely on upregulation at the transcriptional level.
The appearance of fibrosis in lungs of B16F-10-induced animals has been linked to high malignancy and metastasis. We have shown here for the first time that B sensitivum could inhibit the mRNA expression of lysyl oxidase, a copper-containing amine oxidase in B16F-10 melanoma cells. These enzymes deaminate the side chains of lysine residues in collagen and elastin, thereby catalyzing their cross-linking in the extracellular matrix. 38, 39 The increased expression of lysyl oxidase suffices to induce collagen accumulation and fibrosis in vivo. 39 Increased expression of lysyl oxidase has been reported in various metastatic breast cancer cell lines. 40 Previously, we have pointed out that B sensitivum could inhibit the activation and nuclear translocation of activating transcription factor 2 (ATF2) and cyclic adenosine monophosphate response element binding protein (CREB) in B16F-10 cells. 9 Since CREB and ATF2 activation is linked with lysyl oxidase expression, 41 we believe that B sensitivum exerts its effects on lysyl oxidase through some unknown intracellular target/partner. Studies are in progress to define the mechanisms by which B sensitivum exerts its effects on lysyl oxidase and other promoters.
Our results indicate that B sensitivum could inhibit the expression of prolyl hydoxylase, an enzyme that plays an important role in the biosynthesis of collagens. Recently, it has been reported that the hypoxic condition in tumor cells regulates collagen prolyl hydroxylase expression. 42 It has been shown that the hypoxiainducible transcription factor HIFα is regulated by prolyl 4-hydroxylation. 43, 44 Taken together, we expect that the inhibition of prolyl hydroxylase expression of B sensitivum might have some regulatory effect on hypoxia, although the mechanism remains unclear.
Several inflammatory cytokines have been linked with carcinogenesis and tumor initiation, promotion, and metastasis, which suggests that inflammation is associated with cancer development. 45 Numerous studies have indicated that tumor cells exhibit an elevation in the constitutive production of proinflammatory cytokines such as TNF-α, IL-1β, IL-6, and GM-CSF. 46, 47 Our results indicate that B sensitivum could inhibit the expression of these cytokines in metastatic lungs. Regulation of the expression of these cytokines involves the transcription factor nuclear factor-κB (NF-κB). We had previously reported that B sensitivum could inhibit the activation and nuclear translocation of p65, p50, and c-Rel subunits of NF-κB and other transcription factors such as c-fos, ATF2, and CREB protein in B16F-10 melanoma cells. 9 Therefore, it is possible that one of the major steps by which B sensitivum inhibits proinflammatory cytokine expression is through inhibiting the activation and nuclear translocation of transcription factors.
Overall, our results suggest that B sensitivum inhibits tumor cell invasion and motility accompanied by altered expression of MMP-2, MMP-9, prolyl hydroxylase, lysyl oxidase, nm23, ERK-1, ERK-2, STAT-1, VEGF, and proinflammatory cytokines such as TNF-α, IL-1β, IL-6, and GM-CSF. B sensitivum reportedly contains flavonoids, including luteolin 7-methyl ester, iso-orientin, and others; biflavones such as cupressuflavone and amentoflavone; and 2 acids, 4-caffeoylquinic acid and 5-caffeoylquinic acid. 5 The presence of these compounds may contribute to its antimetastatic effect and also demonstrates a possible role of B sensitivum in preventing premalignant cells from becoming malignant.
